Brandl & Talos has advised an investor consortium of Farallon Capital, Adjuvant Capital, Global Health Investment Fund, Hadean Ventures, Omnes Capital, Ventech, Wellington Partners Life Sciences, and High-Tech Grunderfonds.on Themis Bioscience's EUR 40 million Series D financing round. Herbst Kinsky advised Themis Bioscience, and Baker McKenzie advised another investor, MSD, on the deal.
According to Brandl & Talos, the funds are intended to finance a study for a vaccine against the Chikungunya virus, a tropical disease transmitted by mosquitoes, and to develop a new vaccine for oncology and infectious diseases.
The Brandl & Talos team was led by Partner Roman Rericha and Attorney-at-Law Markus Arzt, supported by Attorney Sabine Konrad and Associate Christina Bernhart.
The Baker McKenzie team was led by Partner Eva-Maria Segur-Cabanac.
The Herbst Kinsky team was led by Attorney-at Law Florian Steinhart, supported by Associates Magdalena Wagner and Alexander Holler.
Herbst Kinsky also advised Themis Bioscience on its Series C financing round back in 2018 (as reported by CEE Legal Matters on January 16, 2018) and on its Series B financing round back in 2015 (as reported on December 6, 2016).
